The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells

被引:137
作者
Zhang, CC
Yang, JM
White, E
Murphy, M
Levine, A
Hait, WN [1 ]
机构
[1] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, Piscataway, NJ 08854 USA
[2] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA
[3] Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA
[4] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA
[5] Inst Canc, New Brunswick, NJ 08901 USA
关键词
drug sensitivity; p53; MAP4; microtubule polymerization;
D O I
10.1038/sj.onc.1201658
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mutations in p53 change the sensitivity to cancer chemotherapeutic drugs, Whereas many drugs, including the vinca alkaloids, often become less effective when p53 is transcriptionally inactivated, several, most notably paclitaxel, may become more effective, In studying the underlying mechanism(s), we found that increased MAP4 expression, which occurs with transcriptionally silent p53, is associated with increased sensitivity to paclitaxel and decreased sensitivity to vinca alkaloids, Using murine fibroblasts transfected with MAP4, we directly demonstrated that the changes in drug sensitivity were associated with parallel alterations in drug-induced apoptosis and cell-cycle arrest, Immunofluorescent staining of the microtubule network revealed that cells with increased MAP4 expression displayed an increase in polymerized microtubules and an increased binding of fluorsceinated paclitaxel, Since MAP4 stabilizes polymerized microtubules, overexpression of this gene provides a plausible mechanism to explain the altered sensitivity to microtubule-active drugs in the presence of mutant p53.
引用
收藏
页码:1617 / 1624
页数:8
相关论文
共 43 条
[1]   Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients [J].
Aas, T ;
Borresen, AL ;
Geisler, S ;
SmithSorensen, B ;
Johnsen, H ;
Varhaug, JE ;
Akslen, LA ;
Lonning, PE .
NATURE MEDICINE, 1996, 2 (07) :811-814
[2]   SUPPRESSION OF HUMAN COLORECTAL-CARCINOMA CELL-GROWTH BY WILD-TYPE-P53 [J].
BAKER, SJ ;
MARKOWITZ, S ;
FEARON, ER ;
WILLSON, JKV ;
VOGELSTEIN, B .
SCIENCE, 1990, 249 (4971) :912-915
[3]   DIFFERENTIAL EXPRESSION OF ALTERNATIVELY SPLICED FORMS OF MAP4 - A REPERTOIRE OF STRUCTURALLY DIFFERENT MICROTUBULE-BINDING DOMAINS [J].
CHAPIN, SJ ;
LUE, CM ;
YU, MT ;
BULINSKI, JC .
BIOCHEMISTRY, 1995, 34 (07) :2289-2301
[4]   THYMOCYTE APOPTOSIS INDUCED BY P53-DEPENDENT AND INDEPENDENT PATHWAYS [J].
CLARKE, AR ;
PURDIE, CA ;
HARRISON, DJ ;
MORRIS, RG ;
BIRD, CC ;
HOOPER, ML ;
WYLLIE, AH .
NATURE, 1993, 362 (6423) :849-852
[5]   WILD-TYPE P53 MEDIATES APOPTOSIS BY E1A, WHICH IS INHIBITED BY E1B [J].
DEBBAS, M ;
WHITE, E .
GENES & DEVELOPMENT, 1993, 7 (04) :546-554
[6]   p53 activity and chemotherapy [J].
Delia, D ;
Mizutani, S ;
Lamorte, G ;
Goi, K ;
Iwata, S ;
Pierotti, MA .
NATURE MEDICINE, 1996, 2 (07) :724-725
[7]  
FAN S, 1996, CANCER RES, V55, P1649
[8]  
FAN SJ, 1994, CANCER RES, V54, P5824
[9]  
GEWIRTZ DA, 1993, ONCOL RES, V5, P397
[10]  
GUPTA RS, 1985, JNCI-J NATL CANCER I, V74, P159